Press coverage about Biogen (NASDAQ:BIIB) has trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biogen earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.1840343854189 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Biogen, Inc. – Value Analysis (NASDAQ:BIIB) : December 6, 2017 (finance.yahoo.com)
- Biogen Inc (NASDAQ:BIIB) Engages Mark Hernon As SVP, Chief Information Officer – MMJ Reporter (mmjreporter.com)
- Biogen vet launches cancer drug startup with $50M from GV, others (finance.yahoo.com)
- Biogen (BIIB) PT Set at $350.00 by Oppenheimer (americanbankingnews.com)
- Biogen Inc (NASDAQ:BIIB) And Alkermes Plc (NASDAQ:ALKS) Report License And Collaboration Deal – MMJ Reporter (mmjreporter.com)
Shares of Biogen (NASDAQ BIIB) traded down $5.21 on Wednesday, reaching $314.66. The company had a trading volume of 936,061 shares, compared to its average volume of 1,484,248. The stock has a market capitalization of $67,122.77, a P/E ratio of 14.70, a P/E/G ratio of 1.98 and a beta of 0.73. Biogen has a 1 year low of $244.28 and a 1 year high of $348.84. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.19 and a quick ratio of 1.90.
Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.70 by $0.61. The firm had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Biogen had a return on equity of 38.51% and a net margin of 29.44%. Biogen’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.19 earnings per share. sell-side analysts anticipate that Biogen will post 22.03 earnings per share for the current year.
Several brokerages have recently issued reports on BIIB. Royal Bank Of Canada restated a “hold” rating and issued a $321.00 price objective on shares of Biogen in a research report on Tuesday. Mizuho set a $400.00 target price on Biogen and gave the company a “buy” rating in a research note on Monday, November 13th. Goldman Sachs Group upgraded Biogen from a “buy” rating to a “conviction-buy” rating and set a $338.00 target price for the company in a research note on Wednesday, August 16th. Vetr lowered Biogen from a “buy” rating to a “hold” rating and set a $316.82 target price for the company. in a research note on Monday, September 4th. Finally, Morgan Stanley upgraded Biogen from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $311.00 to $375.00 in a research note on Thursday, October 5th. Twelve analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $344.60.
In other news, Director Alexander J. Denner bought 30,000 shares of Biogen stock in a transaction on Wednesday, November 29th. The shares were bought at an average price of $317.36 per share, with a total value of $9,520,800.00. Following the acquisition, the director now directly owns 10,029 shares in the company, valued at approximately $3,182,803.44. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.25% of the company’s stock.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.